Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/21/2025

Management of Spironolactone-Induced Gynecomastia

Introduction to Alternative Treatments

  • The American College of Cardiology recommends switching from spironolactone to eplerenone to eliminate gynecomastia while maintaining effective blood pressure control in elderly hypertensive patients 1
  • Eplerenone was specifically designed with a 9,11-epoxide group to prevent binding to progesterone and androgen receptors, thereby avoiding gynecomastia and sexual dysfunction 1

Mechanism and Efficacy

  • The European Society of Cardiology notes that spironolactone's non-selective binding to androgen and progesterone receptors causes anti-androgenic effects, leading to gynecomastia 2, 1
  • Eplerenone provides equivalent efficacy for hypertension and resistant hypertension without the gynecomastia risk, as recommended by the American Heart Association 1

Treatment Guidelines

  • The American Heart Association suggests starting eplerenone at an appropriate dose for hypertension (typically 50 mg once daily, may increase to 50 mg twice daily if needed) 1
  • Note that eplerenone may require twice-daily dosing in some patients for adequate blood pressure control, according to the European Heart Journal 1

Alternative Therapies

  • Amiloride (10-40 mg/day) can substitute for spironolactone in patients with gynecomastia, though it is more expensive and less effective than spironolactone metabolites, as reported in Hepatology 3

Important Considerations

  • The European Society of Cardiology advises against discontinuing aldosterone antagonist therapy entirely without replacement, as these patients likely have resistant hypertension or primary aldosteronism requiring mineralocorticoid receptor blockade 2, 1